Amphastar Pharmaceuticals has reported one of its “strongest quarters” with net revenues of $103m for the first quarter ending 31 March 2021, compared to $84m reported in prior-year period. The company has attributed the revenue growth to increase in sales of higher margin products such as Primatene Mist (epinephrine), glucagon and epinephrine injection multi-dose vials.
Jack Zhang, president and CEO of Amphastar, commented that “the launch of glucagon, along with strong sales growth of Primatene...







